Subscribe to RSS
Please copy the URL and add it into your RSS Feed Reader.
https://www.thieme-connect.de/rss/thieme/en/10.1055-s-00035024.xml
Thromb Haemost 2005; 94(06): 1331-1332
DOI: 10.1160/TH05-06-1331
DOI: 10.1160/TH05-06-1331
Case Report
Primary antiphospholipid syndrome and factor V Leiden mutation in a young patient with non-bacterial thrombotic endocarditis and transient ischemic stroke
Further Information
Publication History
Received
14 July 2005
Accepted after revision
13 October 2005
Publication Date:
07 December 2017 (online)
-
References
- 1 Levine JS, Branch DW, Rauch J. The antiphospholipid syndrome. N Engl J Med 2002; 346: 752-63.
- 2 Cervera R, Piette JC, Font J. et al Euro-Phospholipid Project Group. Antiphospholipid syndrome: clinical and immunologic manifestations and patterns of disease expression in a cohort of 1,000 patients. Arthritis Rheum 2002; 46: 1019-27.
- 3 Brenner B, Blumenfeld Z, Markiewicz W. et al Cardiac involvement in patients with primary antiphospholipid syndrome. J Am Coll Cardiol 1991; 18: 931-6.
- 4 Zöller B, Svensson PJ, He X. et al Identification of the same factor V gene mutation in 47 out of 50 thrombosis-prone families with inherited resistance to activated protein C. J Clin Invest 1994; 94: 2521-4.
- 5 Kenet G. et al Factor V Leiden and antiphospholipid antibodies are significant risk factors for ischemic stroke in children. Stroke 2000; 31: 1283-8.
- 6 de Veber G, Monagle P, Chan A. et al Prothrombotic disorders in infants and children with cerebral thromboembolism. Arch Neurol 1998; 55: 1539-43.
- 7 Barreirinho S, Ferro A, Santos M. et al Inherited and acquired risk factors and their combined effects in pediatric stroke. Pediatr Neurol 2003; 28: 134-8.
- 8 Espinosa G. et al Antiphospholipid syndrome: pathogenic mechanisms. Autoimmun Rev 2003; 2: 86-93.
- 9 Meroni PL, Raschi E, Camera M. et al Endothelial activation by aPL: a potential pathogenetic mechanism for the clinical manifestations of the syndrome. J Autoimmun 2000; 15: 237-40.
- 10 Pierangeli SS. et al Thrombogenic effects of antiphospholipid antibodies are mediated by intercellular cell adhesion molecule-1, vascular cell adhesion molecule-1, and P-selectin. Circ Res 2001; 88: 245-50.
- 11 Amengual O, Atsumi T, Khamashta MA. et al The role of the tissue factor pathway in the hypercoagulable state in patients with the antiphospholipid syndrome. Thromb Haemost 1998; 79: 276-81.
- 12 Dizon-Townson D, Hutchison C, Silver R. et al The factor V Leiden mutation which predisposes to thrombosis is not common in patients with antiphospholipid syndrome. Thromb Haemost 1995; 74: 1029-31.
- 13 Ames PR, Tommasino C, D’Andrea G. et al Thrombophilic genotypes in subjects with idiopathic antiphospholipid antibodies: prevalence and significance. Thromb Haemost 1998; 79: 46-49.
- 14 Simantov R. et al Factor V Leiden increases the risk of thrombosis in patients with antiphospholipid antibodies. Thromb Res 1996; 84: 361-5.
- 15 Dahlbäck B. New molecular insights into the genetics of thrombophilia. Thromb Haemost 1995; 74: 139-48.
- 16 Erdogan D. et al Assessment of cardiac structure and left atrial appendage functions in primary antiphospholipid syndrome: a transesophageal echocardiographic study. Stroke 2005; 36: 592-6.
- 17 Nesher G. et al Valvular dysfunction in antiphospholipid syndrome: prevalence, clinical features, and treatment. Semin Arthritis Rheum 1997; 27: 27-35.
- 18 Cervera R. Coronary and valvular syndromes and antiphospholipid antibodies. Thromb Res 2004; 114: 501-7.
- 19 Lopez JA. et al Nonbacterial thrombotic endocarditis: a review. Am Heart J 1987; 113: 773-84.
- 20 Mohr JP, Thompson JL, Lazar RM. et al A comparison of warfarin and aspirin for the prevention of recurrent ischemic stroke. N Engl J Med 2001; 345: 1444-51.